Clinical Trial Update: Efficacy and Safety of Zanubrutinib Plus Tislelizumab Treatment with or Without Sonrotoclax for Patients with Richter Transformation [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating zanubrutinib plus tislelizumab with or without sonrotoclax for Richter transformation; currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Richter Transformation

Drugs mentioned

• Sonrotoclax
• Tislelizumab (tislelizumab)
• Zanubrutinib (zanubrutinib)

Snippet

Sponsor: German CLL Study Group | Conditions: Richter Transformation | Phase 2 | Status: RECRUITING